Immunosuppressive TNI -based reconditioning regimens after graft rejection or graft failure in pediatric patients treated with myeloablative allogeneic hematopoietic cell transplantation.

In the high risk group of patients with graft failure/rejection after allogeneic HCT, the TNI-based reconditioning regimen seems to allow sustained engraftment combined with a favourable toxicity profile leading to long-term OS/EFS. Late toxicity after a median FU of over 7.5 years includes growth failure, manageable hormonal deficiencies and a low risk of decrease of lung function.